

Chronic kidney disease

Review questions

Chapter	Review questions	Outcomes
Measurement of kidney function	What is the accuracy of equations to estimate GFR as a measurement of kidney function?	Critical: <ul style="list-style-type: none"> • Accuracy (P30) • Bias • Precision Important: <ul style="list-style-type: none"> • Sensitivity • Specificity • Area under the curve • Net reclassification index
Markers of kidney damage	What is the best combination of measures of kidney function and markers of kidney damage to identify people with CKD who are at increased risk of progression?	<ul style="list-style-type: none"> • CKD progression: change in eGFR • CKD progression: occurrence of end stage renal disease (ESRD) • Acute Kidney Injury (AKI) • All-cause mortality • Cardiovascular mortality
Classification of CKD	For people with suspected CKD, what is the effect of proteinuria at any given eGFR on adverse outcomes?	Critical: <ul style="list-style-type: none"> • CKD progression: change in eGFR • CKD progression: occurrence of ESRD • All-cause mortality • Cardiovascular mortality • AKI Important: <ul style="list-style-type: none"> • Cardiovascular events • Hospitalisation
Risk factors for adverse outcomes - cause of CKD	For people with CKD, does the presence of; <ul style="list-style-type: none"> • diabetes • hypertension • glomerular disease, or • acute kidney injury (AKI) have an effect on adverse outcomes at any given category of eGFR and ACR?	Critical: <ul style="list-style-type: none"> • CKD progression: change in eGFR • CKD progression: occurrence of ESRD • All-cause mortality • Cardiovascular mortality • Cardiovascular events Important: <ul style="list-style-type: none"> • Hospitalisation
Frequency of monitoring	How frequently should eGFR, ACR or PCR be monitored in people with CKD?	<ul style="list-style-type: none"> • CKD progression: change in eGFR • CKD progression: occurrence of ESRD • All-cause mortality • Cardiovascular mortality
Progression/ development of CKD after AKI	What is the risk of developing and/or progression of CKD after an episode of AKI?	<ul style="list-style-type: none"> • Incident CKD • CKD progression: change in eGFR • CKD progression: occurrence of ESRD
Low protein diet	For people with CKD, are low protein diets a clinically and cost effective method for the management of CKD?	Critical: <ul style="list-style-type: none"> • CKD progression: change in eGFR

Chapter	Review questions	Outcomes
		<ul style="list-style-type: none"> • CKD progression: occurrence of ESRD • All-cause mortality • Cardiovascular mortality • Health related quality of life <p>Important:</p> <ul style="list-style-type: none"> • Compliance (measured by actual protein intake) • Nutritional status (measured by subjective global assessment) • Nutritional status (measured by change in BMI)
Self-management support systems	For people with CKD, what is the clinical and cost effectiveness of self-management support systems?	<p>Critical:</p> <ul style="list-style-type: none"> • CKD progression: change in eGFR • CKD progression: occurrence of ESRD • All-cause mortality • Cardiovascular mortality • Health related quality of life • Hospitalisation <p>Important:</p> <ul style="list-style-type: none"> • Adherence (to treatments) • Outpatient attendance (including frequency of attendance)
Renin-angiotensin-aldosterone system antagonists in the management of CKD	For people with CKD, what is the clinical and cost effectiveness of renin-angiotensin-aldosterone system antagonists in the management of CKD?	<p>Critical</p> <ul style="list-style-type: none"> • CKD progression: change in eGFR • CKD progression: occurrence of ESRD • All-cause mortality • Cardiovascular mortality • Cardiovascular events • Occurrence of AKI <p>Important</p> <ul style="list-style-type: none"> • Change in proteinuria • Hospitalisation • Health related quality of life
Reducing cardiovascular disease: Antiplatelets and anticoagulants	For people with CKD, what is the clinical and cost effectiveness of oral antiplatelet and anticoagulant therapy in reducing cardiovascular disease?	<p>Critical:</p> <ul style="list-style-type: none"> • Cardiovascular/cerebrovascular events • Major bleeding (as reported by the studies) • All-cause mortality • Cardiovascular mortality <p>Important:</p> <ul style="list-style-type: none"> • CKD progression: change in eGFR • CKD progression: occurrence of ESRD • Minor bleeding (as reported by the studies) • Hospitalisation • Health related quality of life
Asymptomatic hyperuricaemia	For people with CKD and asymptomatic hyperuricaemia, what is the clinical and	<p>Critical:</p> <ul style="list-style-type: none"> • CKD progression: change in eGFR

Chapter	Review questions	Outcomes
	cost effectiveness of uric acid lowering with allopurinol or febuxostat in the management of CKD?	<ul style="list-style-type: none"> • CKD progression: occurrence of ESRD • Cardiovascular events • Reduction in antihypertensive agents • All-cause mortality • Cardiovascular mortality <p>Important:</p> <ul style="list-style-type: none"> • Hospitalisation • Health related quality of life
Vitamin D	For people with GFR 15-60, what is the clinical and cost-effectiveness of vitamin D supplementation for the management of renal bone disease?	<p>Critical:</p> <ul style="list-style-type: none"> • All-cause mortality • Cardiovascular mortality • Cardiovascular events • Fracture • CKD progression: change in eGFR • CKD progression: occurrence of ESRD • Hypercalcaemia (serum calcium >2.5 mmol/litre) <p>Important:</p> <ul style="list-style-type: none"> • Hospitalisation • Health related quality of life
Oral bicarbonate supplements for the management of CKD	What is the clinical and cost effectiveness of oral bicarbonate supplements in the management of CKD?	<p>Critical:</p> <ul style="list-style-type: none"> • CKD progression: change in eGFR or creatinine clearance • CKD progression: occurrence of ESRD • All-cause mortality • Cardiovascular mortality • Cardiovascular events (including chronic heart failure) • Hypertension (measured by use of antihypertensives) <p>Important:</p> <ul style="list-style-type: none"> • Alkalosis • Nutritional status (measured by subjective global assessment) • Nutritional status (measured by change in BMI) • Hospitalisation • Health related quality of life